CD19-targeting fusion protein combined with PD1 antibody enhances anti-tumor immunity in mouse models.

ABSTRACT: In our previous studies, using a B cell vaccine (scFv-Her2), the targeting of tumor-associated antigen Her2 (human epidermal growth factor receptor-2) to B cells via the anti-CD19 single chain variable fragment (scFv) was shown to augment tumor-specific immunity, which enhanced tumor control in the prophylactic and therapeutic setting. However, the fusion protein displayed limited activity against established tumors, and local relapses often occurred following scFv-Her2 treatment, indicating that scFv-Her2-induced responses are inadequate to maintain anti-tumor immunity. In this study, targeting the IV region (D4) of the extracellular region of Her2 to B cells via CD19 molecules (scFv-Her2_D4) was found to enhance IFN-γ-producing-CD8⁺ T cell infiltration in tumor tissu

SUBMITTER: Lv Z 

PROVIDER: S-EPMC7185221 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature